Envoy Medical Receives FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data
White Bear Lake, Minnesota--(Newsfile Corp. - October 7, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to expand the Company's pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage based on promising three-month data from the first 10 patients. The
Biotechnology, Healthcare and Hospitals
2025-10-07 8:00 AM EDT | Envoy Medical, Inc.
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder va
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-06 7:00 AM EDT | Cannabis Bioscience International Holdings
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-06 7:00 AM EDT | Optimi Health Corp.
Aires Partnership with WWE Creates First-Ever EMF-Friendly WWE Wrestling Match & Measurable Business Results
Toronto, Ontario--(Newsfile Corp. - October 6, 2025) - American Aires Inc. (CSE:WIFI) (OTCQB:AAIRF) ("Aires" or the "Company"), a pioneer
2025-10-06 6:00 AM EDT | American Aires Inc.
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025. At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners acro
Biotechnology, Pharmaceuticals, Health
2025-10-06 3:15 AM EDT | Defence Therapeutics Inc.
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation to its non-brokered private placement unit offering
2025-10-03 5:00 AM EDT | Marvel Biosciences Corp.
Canadian-made Stable Isotopes: TMC Group Attends EANM 2025 to Strengthen Global Supply Chains
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2025) - TMC Group, a manufacturer of high-purity stable isotopes, is attending the European Association of Nuclear Medicine (EANM) 2025 Annual Congress, October 4-8 in Barcelona. TMC Group's enriched stable isotopes have been supporting groundbreaking scientific research and innovation around the world since 2004. "We've been quietly providing a safe, reliable supply of enriched stable isotopes to world-leading researchers and li
Technology, Biotechnology, Chemical, Pharmaceuticals
2025-10-02 10:00 AM EDT | TMC Group
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building
Biotechnology, Pharmaceuticals, Health
2025-10-02 3:15 AM EDT | Defence Therapeutics Inc.
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources ("DERs"). Over $50 million has been invested since 2019 to commercialize this revolutionary autonomous platform delivering Dynamic
Biotechnology, Pharmaceuticals
2025-10-01 8:30 AM EDT | Entero Therapeutics, Inc.
Envoy Medical to Participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) Conference on October 11th-14th
White Bear Lake, Minnesota--(Newsfile Corp. - October 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that management will participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) conference taking place on October 11th-14th, 2025 in Indianapolis, IN, at the Indiana Convention Center and JW Marriott Indianapolis
Biotechnology, Healthcare and Hospitals
2025-10-01 8:00 AM EDT | Envoy Medical, Inc.
Former Canadian Coatings Association President & CEO Gary LeRoux joins Biosenta's Advisory Board
Ontario and Calgary, Alberta--(Newsfile Corp. - October 1, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today announced that Gary LeRoux, past President and CEO of the Canadian Coatings Association (CCA), has joined the company's advisory board.
Biotechnology, Chemical, Household / Consumer / Cosmetics
2025-10-01 8:00 AM EDT | Biosenta Inc.
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it has entered into a definitive Asset Purchase Agreement (the "Agreement") for the sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a well-established global pharmaceutical co
Biotechnology, Pharmaceuticals
2025-10-01 8:00 AM EDT | PharmaTher Holdings Ltd.
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that it has signed debt-to-equity conversion agreements with vendors to convert approximately CAD $13.3 million of outstanding accounts payable debt into equity of Sernova. T
2025-10-01 7:00 AM EDT | Sernova Biotherapeutics
Scryb Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") announces that it has granted 3,870,000 stock options (the "Options") to various employees, directors, officers and consultants of the Company. Each Option is exercisable at a price of $0.12 for one common share of the Company (each a "Common Share") for a period of five years from the da
Biotechnology, Healthcare and Hospitals, Health
2025-09-30 8:04 PM EDT | Scryb Inc.
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announces the relocation and expansion of its clinical laboratories and offices from the MaRS startup incubation hub into a new, state-of-the-art clinical laboratory space in the Greater Toronto Area. The relocati
2025-09-30 4:30 PM EDT | Telo Genomics Corp.
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting feedback from UK MHRA In principle, UK MHRA accepts use of historical control arm to support conditional MAA UK MHRA conditional MAA and US FDA Biologics Licensing Application (BLA) submissions expected to be completed wit
2025-09-30 7:40 AM EDT | OS Therapies
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents in both China and Japan. These new patents cover its innovative metabolic liquid biopsy platform for the rapid, non-invasive detection of lung cancer. The newly granted Chinese patent (N° ZL 201980092723.X) a
Technology, Biotechnology, Healthcare and Hospitals
2025-09-29 8:30 AM EDT | BioMark Diagnostics, Inc.
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas healthcare is experiencing a historic breakthrough with the approval of House Bill 46 (HB 46). Signed into law on June 21, 2025, by Governor Greg Abbott, the expansion of the Texas Compassionate Use Program (TCUP) will cover chronic pain, PTSD, and degenerative neurological conditions, among othe
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-09-29 7:00 AM EDT | Cannabis Bioscience International Holdings
Quantum BioPharma Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-26 8:00 PM EDT | Quantum BioPharma Ltd.
Scryb Closes Oversubscribed Private Placement for over $1.4M
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company"), is pleased to announce it has completed its previously announced upsized non-brokered private placement offering, issuing 14,709,700 units of the Company (each, a "Unit"), at a price of $0.10 per Unit, for gross proceeds of $1,470,970 (the "Offering"). The original offering was announced for up to 6,000,000 Units of the Company on September 17, 2025, and
Biotechnology, Healthcare and Hospitals, Health
2025-09-26 7:03 PM EDT | Scryb Inc.